Aptamer conjugates for targeted degradation of osteosclerosis proteins
CN122094697APending Publication Date: 2026-05-26APTACURE THERAPEUTICS LTD
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- CN202480066127.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-11-01
- Filing Date
- 2024-11-01
- Publication Date
- 2026-05-26
AI Technical Summary
Technical Problem
The existing osteosclerotic protein targeted therapy technology has the problems of high immunogenicity, high production costs, unstable and ineffective degradation of osteosclerotic proteins in cells.
Method used
Aptamer conjugate is developed that contains aptamer specifically binding to osteosclerotic proteins and specific ligands of E3 ubiquitin ligase or asialicol glycoprotein receptors to degrade osteosclerotic proteins through targeted protein degradation pathways.
Benefits of technology
It has achieved effective degradation of osteosclerosis protein intracellularly, with the advantages of low immunogenicity, low production cost and high stability, and can significantly inhibit the biological activity of osteosclerosis protein in vitro and in vivo.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 00000049_0000 
Figure 00000050_0000 
Figure 00000051_0000
Abstract
The present invention relates to aptamer conjugates for targeted degradation of sclerostin, and more particularly, to aptamer conjugates for targeted degradation of sclerostin. In particular, the present invention relates to conjugates of aptamers directed to osteosclerosis proteins and ligands capable of targeting the protein degradation pathway, and uses of the conjugates for degrading osteosclerosis proteins.
Need to check novelty before this filing date? Find Prior Art